Mircera approved for monthly dosing in ESA-naive patients

The renal anaemia treatment Mircera (methoxypolyethyleneglycol-epoetin beta) can now be administered once monthly in patients who are not on dialysis and are not currently receiving an erythropoiesis-stimulating agent. At this dosing interval, the recommended dose is 1.2 microgram/kg by subcutaneous injection.

The long-acting erythropoietin receptor activator was previously licensed only for fortnightly dosing in this population.

View Mircera drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases